Lupin’s first-quarter net profit soared nearly 50%, but the strong performance was overshadowed by concerns about regulatory overhang and slower-than-expected scale-up of new products that could jeopardize future revenue growth momentum.

Aurobindo Pharma says its billion-dollar purchase of Sandoz’s US business is on track for completion “very soon” as it announced net first-quarter net profit that rocketed by nearly 40%, powered by strong US sales.

Mallinckrodt has put on hold its plan to spin off its specialty generics business due to investor worries about potentially big payouts arising from ongoing US opioids litigation.

Bausch Health has settled its patent litigation with Teva over the Canadian firm’s ulcerative colitis medicine Apriso (mesalamine) 375mg extended-release capsules. The deal gives Teva the right to market a generic version of Apriso in the US in 2021, nine years before the patent on the drug expires.

Unichem Laboratories has joined a growing list of Indian firms entering China. The firm has set up a wholly-owned subsidiary to sell generic formulations and APIs.

AstraZeneca has petitioned a US court to stop India’s Dr Reddy’s from launching a generic version of its blood clot-fighting drug Brilinta, accusing the Indian drugmaker of patent infringement.